Antiviral Agents

Antiviral Agents

1st Edition - July 22, 2013

Write a review

  • Editor: Erik De Clercq
  • eBook ISBN: 9780124055377

Purchase options

Purchase options
DRM-free (EPub, Mobi, PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

This new volume of Advances in Pharmacology explores the current state of antiviral agents. Chapters cover such topics as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Key Features

  • Explores the current state of anti-viral agents
  • Chapters cover a variety of topics such as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV
  • With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike

Readership

Pharmacologists, immunologists, and biochemists

Table of Contents

  • Preface

    References

    Contributors

    Chapter One. Antiviral Agents for Herpes Simplex Virus

    Abbreviations

    1 Introduction

    2 Historical Overview: Therapies for HSV Infections

    3 Clinical Experience with ACV, VACV, and FCV Through Two Decades

    4 Antiviral Drug Resistance

    5 Novel Approaches to HSV Chemotherapy

    6 Prospects for Novel Antiviral Compounds and Vaccines

    7 Conclusion

    Conflict of Interest

    References

    Further Reading

    Chapter Two. Nucleotide Prodrugs for the Treatment of HCV Infection

    Abbreviations

    1 Introduction

    2 Nucleoside Inhibitors

    3 Nucleotide Prodrugs

    4 Conclusion

    Conflict of Interest

    References

    Chapter Three. HIV Integrase Inhibitors: 20-Year Landmark and Challenges

    Abbreviations

    1 Introduction

    2 Requirement of IN for HIV Replication

    3 IN Structure

    4 The INSTIs

    5 Challenges

    6 Conclusion

    Conflict of Interest

    References

    Chapter Four. Advances in the Treatment of Varicella-Zoster Virus Infections

    Abbreviations

    1 Introduction

    2 Vaccination Strategies and Postexposure Prophylaxis

    3 Existing Antiviral Treatments

    4 Medical Need for New Anti-VZV Agents

    5 Development of Novel Anti-VZV Agents

    6 Candidate Anti-VZV Drugs

    7 Perspectives

    8 Conclusion

    Conflict of Interest

    Acknowledgments

    References

    Chapter Five. Hepatitis C Virus: Standard-of-Care Treatment

    Abbreviations

    1 Introduction

    2 Curing HCV Infection

    3 Interferons

    4 Ribavirin

    5 Direct HCV Inhibitors (DAAs and HTAs)

    6 Interferon-Based Strategies in 2013

    7 Interferon-Free Regimens in 2014 and Onward

    8 Conclusion

    Conflict of Interest

    References

    Chapter Six. Influenza Virus Resistance to Antiviral Therapy

    Abbreviations

    1 Introduction

    2 Antiviral Drugs Under Development

    3 Resistance to Antiviral Therapy

    4 Mechanisms of Resistance to NAIs

    5 Permissive and Compensatory Mechanisms Governing Primary Resistance

    6 Effectiveness of NAIs

    7 Conclusion

    Conflict of Interest

    References

    Further Reading

    Chapter Seven. The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

    Abbreviations

    1 Introduction

    2 A Flashback from the Discovery of HBV to the Recognition of the Wide Spectrum of Chronic HBV Infection

    3 Development of Chronic HBV Infection and the Phases in Its Natural Course

    4 Complicating and Associated Conditions and Comorbidities

    5 Treatment of CHB

    6 Future Treatments for CHB

    7 Conclusion

    Conflict of Interest

    References

    Chapter Eight. The Holý Trinity: The Acyclic Nucleoside Phosphonates

    Abbreviations

    1 Introduction

    2 HPMPA

    3 Cidofovir

    4 Adefovir

    5 Tenofovir

    6 Tenofovir Combinations

    7 Tenofovir for the Prevention of HIV Infections

    8 Tenofovir for the Treatment of HBV Infections

    9 Tenofovir for PMTCT

    10 Tenofovir Toxicity

    11 GS-7340, GS-9131, GS-9191, GS-9219

    12 Conclusion

    Conflict of Interest

    Acknowledgments

    References

    Chapter Nine. The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)

    Abbreviations

    1 Introduction

    2 Reverse Transcriptase

    3 Nucleoside Reverse Transcriptase Inhibitors

    4 Nonnucleoside Reverse Transcriptase Inhibitors

    5 Protease Inhibitors

    6 Drug Combinations

    7 Clinical Aspects

    8 Preexposure Prophylaxis

    9 Prevention of Mother-to-Child Transmission

    10 Children

    11 Toxicity

    12 Adherence (Compliance)

    13 Resistance

    14 New NRTIs, NNRTIs, and PIs

    15 Conclusion

    Conflict of Interest

    Acknowledgments

    References

    Index

Product details

  • No. of pages: 384
  • Language: English
  • Copyright: © Academic Press 2013
  • Published: July 22, 2013
  • Imprint: Academic Press
  • eBook ISBN: 9780124055377

About the Editor

Erik De Clercq

Ratings and Reviews

Write a review

There are currently no reviews for "Antiviral Agents"